NCT05426252 is a Phase 1, PHASE2 clinical trial of Abatacept in Thalassemia in Children, sponsored by The Hospital for Sick Children.

Who is sponsoring NCT05426252?

NCT05426252 is sponsored by The Hospital for Sick Children.

What drugs are being tested in NCT05426252?

Interventions in NCT05426252: Abatacept, Sirolimus.

What condition does NCT05426252 study?

NCT05426252 studies Thalassemia in Children.

Is NCT05426252 still recruiting?

NCT05426252 is currently recruiting now. Last updated 19 December 2023.

Last reviewed 2023-12-19 · How we verify

NCT05426252

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Thal-Fabs: Reduced Toxicity Conditioning for High Risk Thalassemia

Recruiting now Phase 1, PHASE2 Last updated 19 December 2023

What this trial tests

Phase 1, PHASE2 trial testing Abatacept in Thalassemia in Children in 20 participants. Currently enrolling.

Timeline

22 March 2022

Primary endpoint
31 December 2025

31 December 2026

Quick facts

Lead sponsor	The Hospital for Sick Children
Phase	Phase 1, PHASE2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	22 March 2022
Primary completion	31 December 2025
Estimated completion	31 December 2026
Sites	1 location across Canada

Drugs / interventions tested

Abatacept (abatacept) — full drug profile →
Sirolimus (sirolimus) — full drug profile →

Conditions studied

Thalassemia in Children — all drugs for Thalassemia in Children →

Sponsor

The Hospital for Sick Children

Who can join

Adults 1 to 18, any sex, with Thalassemia in Children. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate a novel transplant strategy for the long-term benefit of patients with transfusion dependent high-risk thalassemia.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Role of abatacept in the prevention of graft-<i>versus</i>-host disease: current perspectives.
Ngwube A, Rangarajan H, Shah N. · · 2023 · cited 16× · PMID 36845849 · DOI 10.1177/20406207231152644
Early Engraftment and Immune Kinetics Following Allogeneic Transplant Using a Novel Reduced-Toxicity Transplant Strategy in Children/Adolescents with High-Risk Transfusion-Dependent Thalassemia: Early Results of the ThalFAbS Trial.
Raffa EH, Harris TM, Choed-Amphai C, Kirby-Allen M, et al · · 2025 · PMID 39722321 · DOI 10.1016/j.jtct.2024.12.016

Verify or expand the search:

Other trials of Abatacept

Trials testing the same drug.

NCT07366801 — Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus H · Phase 2, PHASE3 · recruiting
NCT06680661 — ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis · Phase 2 · recruiting
NCT06929039 — Open Label , Randomized, Three Arm Parallel Group Single Dose Comparative Pharmacokinetic , Safety and Immunogenicity St · Phase 1 · completed
NCT06008808 — Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release S · Phase 1 · recruiting
NCT03929601 — Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes · Phase 2 · active not recruiting

Other The Hospital for Sick Children trials

Trials by the same sponsor.

NCT07454681 — MRI Assessment of Lung Airways in Cystic Fibrosis: Evaluate MRI's Ability to Detect Changes in Airway Structure . · not yet recruiting
NCT07452575 — 3D Ultrasound in Hemophilic Ankles · NA · not yet recruiting
NCT07508826 — AI-assisted Endotracheal Intubation · NA · not yet recruiting
NCT07345819 — Dexamethasone vs. Placebo in Children and Youth Hospitalized for Orbital Cellulitis · NA · not yet recruiting
NCT07497178 — MRgFUS for Childhood Epilepsy · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05426252 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The Hospital for Sick Children
Last refreshed: 19 December 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05426252.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing